Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.
Verywell Health on MSN9mon
What Is Indolent Systemic Mastocytosis?
Indolent systemic mastocytosis (ISM) is one of the five subtypes of systemic mastocytosis, a condition characterized by the ...
Hosted on MSN3mon
Advances in systemic mastocytosis: Early signs of efficacy for novel drug and new predictive tool to guide patient care
Systemic mastocytosis (SM) is characterized by an abnormal accumulation of mast cells, a type of immune cell present throughout the body that contributes to allergic and inflammatory responses ...
Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock
Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...
Yahoo Finance1mon
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
“The expanded SUMMIT data presented at AAAAI 2025 reinforce our belief that bezuclastinib can rapidly and meaningfully improve a wide variety of symptoms that impact the daily lives of patients with ...